EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access · CC BY 4.0

Preclinical and clinical evidence for suppression of alcohol intake by apremilast

Kolter B Grigsby, Regina A Mangieri, Amanda J Roberts, Marcelo F Lopez, Evan J Firsick, Kayla G Townsley, Alan Beneze, Jessica Bess, Toby K Eisenstein, Joseph J Meissler, John M Light, Jenny Miller und 11 weitere

Journal of Clinical Investigation · 15.03.2023 · 133 (6)

DOI: 10.1172/jci159103 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Investigation, online erschienen am 15.03.2023. Verfasst von Kolter B Grigsby und 22 weiteren Autor:innen. Beteiligte Einrichtung: Portland Alcohol Research Center, Department of Behavioral Neuroscience, Oregon Health & Science University, and VA Portland Health Care System, Port…. Hauptthemen laut MEDLINE: Alcoholism, Phosphodiesterase 4 Inhibitors, Psoriasis. Die Arbeit wurde bisher 66-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAAA NIH HHS, BLRD VA, National Institute on Alcohol Abuse and Alcoholism.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Treatment options for alcohol use disorders (AUDs) have minimally advanced since 2004, while the annual deaths and economic toll have increased alarmingly. Phosphodiesterase type 4 (PDE4) is associated with alcohol and nicotine dependence. PDE4 inhibitors were identified as a potential AUD treatment using a bioinformatics approach. We prioritized a newer PDE4 inhibitor, apremilast, as ideal for repurposing (i.e., FDA approved for psoriasis, low incidence of adverse events, excellent safety profile) and tested it using multiple animal strains and models, as well as in a human phase IIa study. We found that apremilast reduced binge-like alcohol intake and behavioral measures of alcohol motivation in mouse models of genetic risk for drinking to intoxication. Apremilast also reduced excessive alcohol drinking in models of stress-facilitated drinking and alcohol dependence. Using site-directed drug infusions and electrophysiology, we uncovered that apremilast may act to lessen drinking in mice by increasing neural activity in the nucleus accumbens, a key brain region in the regulation of alcohol intake. Importantly, apremilast (90 mg/d) reduced excessive drinking in non-treatment-seeking individuals with AUD in a double-blind, placebo-controlled study. These results demonstrate that apremilast suppresses excessive alcohol drinking across the spectrum of AUD severity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlcoholismPhosphodiesterase 4 InhibitorsPsoriasisHumansMiceAnimalsThalidomideEthanolAlcohol Drinking

Stichwörter der Autor:innen

AddictionClinical TrialsDrug therapyNeuroscience

Substanzen

apremilastThalidomidePhosphodiesterase 4 InhibitorsEthanol

Autor:innen und Institutionen

  • Portland Alcohol Research Center, Department of Behavioral Neuroscience, Oregon Health & Science University, and VA Portland Health Care System, Portland, Oregon, USA.
  • Waggoner Center for Alcohol and Addiction Research, Division of Pharmacology and Toxicology, College of Pharmacy, The University of Texas at Austin, Austin, Texas, USA.
  • Animal Models Core Facility, The Scripps Research Institute, La Jolla, California, USA.
  • Charleston Alcohol Research Center, Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina, USA.
  • Pearson Center for Alcoholism and Addiction Research, Department of Molecular Medicine, The Scripps Research Institute, La Jolla, California, USA.
  • Center for Substance Abuse Research, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania, USA.

Förderung

  • NIAAA NIH HHS
  • BLRD VA
  • National Institute on Alcohol Abuse and Alcoholism
  • National Institute on Drug Abuse
  • US Department of Veterans Affairs Grants

Zitieren

APA

Grigsby, K. B., Mangieri, R. A., Roberts, A. J., Lopez, M. F., Firsick, E. J., Townsley, K. G., Beneze, A., Bess, J., Eisenstein, T. K., Meissler, J. J., Light, J. M., Miller, J., Quello, S., Shadan, F., Skinner, M., Aziz, H. C., Metten, P., Morrisett, R. A., Crabbe, J. C., …, & Ozburn, A. R. (2023). Preclinical and clinical evidence for suppression of alcohol intake by apremilast. Journal of Clinical Investigation, 133(6). https://doi.org/10.1172/jci159103

Vancouver

Grigsby KB, Mangieri RA, Roberts AJ, Lopez MF, Firsick EJ, Townsley KG, et al. Preclinical and clinical evidence for suppression of alcohol intake by apremilast. Journal of Clinical Investigation. 2023;133(6). doi:10.1172/jci159103

BibTeX
@article{Grigsby2023,
  author = {Grigsby, Kolter B and Mangieri, Regina A and Roberts, Amanda J and Lopez, Marcelo F and Firsick, Evan J and Townsley, Kayla G and Beneze, Alan and Bess, Jessica and Eisenstein, Toby K and Meissler, Joseph J and Light, John M and Miller, Jenny and Quello, Susan and Shadan, Farhad and Skinner, Michael and Aziz, Heather C and Metten, Pamela and Morrisett, Richard A and Crabbe, John C and Roberto, Marisa and Becker, Howard C and Mason, Barbara J and Ozburn, Angela R},
  title = {Preclinical and clinical evidence for suppression of alcohol intake by apremilast},
  journal = {Journal of Clinical Investigation},
  year = {2023},
  volume = {133},
  number = {6},
  doi = {10.1172/jci159103}
}
Kostenlos starten →